Ellington Management Group LLC Acquires Shares of 24,700 TG Therapeutics Inc (TGTX)

Ellington Management Group LLC purchased a new stake in TG Therapeutics Inc (NASDAQ:TGTX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 24,700 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Senzar Asset Management LLC boosted its stake in TG Therapeutics by 56.9% during the fourth quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock worth $11,112,000 after acquiring an additional 491,678 shares in the last quarter. University of Notre Dame DU Lac bought a new position in TG Therapeutics during the fourth quarter worth $2,483,000. Goldman Sachs Group Inc. boosted its stake in TG Therapeutics by 1,335.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 311,793 shares of the biopharmaceutical company’s stock worth $2,557,000 after acquiring an additional 290,066 shares in the last quarter. Kennedy Capital Management Inc. boosted its stake in TG Therapeutics by 39.0% during the fourth quarter. Kennedy Capital Management Inc. now owns 585,439 shares of the biopharmaceutical company’s stock worth $4,801,000 after acquiring an additional 164,210 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in TG Therapeutics by 176.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 243,485 shares of the biopharmaceutical company’s stock worth $2,886,000 after acquiring an additional 155,535 shares in the last quarter. Hedge funds and other institutional investors own 47.33% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several research analysts recently issued reports on TGTX shares. ValuEngine raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research note on Monday, January 8th. Finally, B. Riley reiterated a “buy” rating and issued a $21.50 target price on shares of TG Therapeutics in a report on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. TG Therapeutics currently has a consensus rating of “Buy” and an average target price of $24.60.

NASDAQ TGTX traded up $0.30 during trading hours on Thursday, reaching $14.30. 946,115 shares of the company were exchanged, compared to its average volume of 1,560,024. TG Therapeutics Inc has a 1 year low of $7.25 and a 1 year high of $17.35. The company has a market capitalization of $993.87, a PE ratio of -7.49 and a beta of 1.20.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, hitting the consensus estimate of ($0.46). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. research analysts predict that TG Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ellington Management Group LLC Acquires Shares of 24,700 TG Therapeutics Inc (TGTX)” was originally reported by Macon Daily and is the property of of Macon Daily. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://macondaily.com/2018/04/12/ellington-management-group-llc-purchases-new-stake-in-tg-therapeutics-inc-tgtx-updated-updated-updated.html.

TG Therapeutics Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply